Article
Immune Checkpoint Blockade and Biomarkers of Response in Lymphoma: A Case-Illustrated Narrative Review
2023-05-17
Abstract excerpt
Immune checkpoint blockade (ICB) has revolutionized the prognosis of several advanced-stage solid tumors. However, its success has been far more limited in hematological malignancies and is mostly restricted to classical Hodgkin lymphoma (cHL) and primary mediastinal B cell lymphoma (PMBCL). In patients with non-Hodgkin lymphoma (NHL), response to PD-1/PD-L1 ICB monotherapy has been relatively limited, although so...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- a999e01c-73db-5123-a82c-547efd911420
- DOI
- 10.20944/preprints202305.1239.v1
